LivaNova PLC
LIVN
Positions held
Your positionsLIVN isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- LivaNova PLC operates in the medical devices sector, which is experiencing growth due to increasing demand for innovative healthcare solutions.
- Revenue increased by 8% compared to the prior quarter, reaching $391 million.
- Gross margin improved to 70.1%, up from 67.3% in the previous quarter.
- The company has a 'Strong Sell' signal with a score of -23.00, indicating significant bearish sentiment.
- Net income for 2025 was reported at -242.471 million, reflecting ongoing financial challenges.
- Operating margin for 2023 was only 1.86%, highlighting operational inefficiencies.
Fundamentals
| Market cap | $4.17B | Enterprise value | $4.02B | Trailing P/E | 22.46 | Forward P/E | 16.21 |
| PEG | 0.93 | Price / book | 3.15 | Beta | 0.88 | Dividend yield | 0.00% |
| Revenue growth | 10.8% | Earnings growth | 287.8% | Gross margin | 67.7% | Operating margin | 13.5% |
| Profit margin | 12.8% | ROE | 15.4% | ROA | 5.0% | Debt / equity | 0.27 |
| Current ratio | 1.45 | Free cash flow | $59.87M | Analyst recommendation | buy | Mean target | $90.55 |
| 52w high | $85.76 | 52w low | $48.82 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $391M | $362M | $361M | $358M | $353M | — |
| Op margin | 12.7% | 11.4% | 11.8% | 15.1% | 15.4% | — |
| Net income | $109M | $22.3M | $30.9M | $26.8M | $27.2M | — |
| Gross margin | 70.1% | 67.3% | 66.4% | 68.4% | 67.8% | — |
| Gross profit | $274M | $244M | $240M | $245M | $239M | — |
| Operating income | $49.5M | $41.5M | $42.6M | $54.0M | $54.2M | — |
- Revenue +8% vs prior quarter ($391M vs $362M).
- Gross margin 70.1% (was 67.3% prior quarter).
- Operating margin expanded to 12.7%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.4B | $1.3B | $1.2B | $1.0B | — |
| Op margin | 14.4% | 10.3% | 1.9% | 5.2% | — |
| Net income | -$242M | $63.2M | $17.5M | -$86.2M | — |
| Gross margin | 67.7% | 68.1% | 65.5% | 69.2% | — |
| Gross profit | $940M | $853M | $756M | $707M | — |
| Operating income | $199M | $129M | $21.5M | $52.6M | — |
Headlines — positive tone
• [OK · fundamentals] LivaNova PLC (LIVN) (Q2 2026) Earnings Call Highlights: Record Revenue and EPS, Raised Guidance ...
News
2026-10-07 · Flutter upgraded, AppFolio downgraded: Wall Street's top analyst calls
2026-09-24 · Operating Leverage and Product Innovation Drive LivaNova’s(LIVN) Sustained Profit Outlook
2026-09-23 · LivaNova to Announce Third-Quarter 2026 Results
2026-09-14 · Livanova Insider Sold Shares Worth $273,032, According to a Recent SEC Filing
2026-09-11 · LivaNova Director Sells 1,650 Shares for $131,500
2026-09-08 · GHO Capital appoints Vivid Sehgal as Operating Partner
2026-09-03 · LivaNova to Present at Morgan Stanley and Baird Healthcare Conferences in September
2026-08-17 · NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth
2026-08-17 · Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated?
2026-08-12 · Stronger Q2 Results And New Supply Deal Might Change The Case For Investing In LivaNova (LIVN)
2026-08-12 · LivaNova (LIVN) Could Be 5% Undervalued Following Raised 2026 Guidance
2026-08-12 · LivaNova (LIVN) Q2 2026 Earnings Call Transcript
Price (daily)
Full chart · RSI · MACD · patterns